Spotlight -

Downstream Processing|

Upstream Processing

|Articles|October 15, 2002

BioPharm International

BioPharm International-10-01-2002
Volume 15
Issue 10

Revolutionizing Biologics Regulation

Author(s)Jill Wechsler

by Jill Wechsler

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 23 years ago

Article

FDA Launches Major CGMP Review

almost 23 years ago

Article

Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)

almost 23 years ago

Article

Process Validation: How Much to Do and When to Do It

almost 23 years ago

Article

Biotech Will Recover!

almost 23 years ago

Article

Preparing Biological Product Deviation Reports: Suggestions for Manufacturers

almost 23 years ago

Article

GMPs and Pharmaceutical Labeling

almost 23 years ago

Article

Survival Guide to FDA Inspections: Part 2, Conducting the Audit ? Ready or Not, Here They Come

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Trending on BioPharm International

Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs

How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia

Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms

Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care

$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access

© 2025 MJH Life Sciences^®

All rights reserved.